Pharmaceutical companies are postponing or withdrawing some European product launches as uncertainty over US pricing policy reshapes global commercial calculations and adds to pressure on Europe’s medicines market.
Some pharmaceutical companies are delaying the launch of new medicines in Europe as they assess the effect of US President Donald Trump’s drug pricing reforms on global revenues and pricing strategy. The administration’s “most-favoured-nation” approach, which links US prices to lower prices abroad, has led some companies to reconsider whether launching early in Europe could weaken their position in the more profitable US market.
New drug launches in EU markets fell by about 35% in the ten months after the US introduced international reference pricing in May 2025, compared with the previous ten months, based on the analysis by GlobalData. Some companies now see a commercial case for delaying or cancelling lower-priced European launches in order to avoid affecting future US pricing benchmarks.
The issue matters because Europe is already trying to shorten delays in patient access to innovative medicines while also addressing medicine shortages and concerns about industrial competitiveness. The European Commission says its pharmaceutical reform, which reached political agreement in December 2025, is intended to modernise the bloc’s rules, strengthen competitiveness and innovation, and improve security of supply. Separately, the Commission’s Critical Medicines Act, proposed in March 2025, is meant to improve the availability, supply and production of critical medicines in the EU and to address cases where some medicines are not available in certain markets.
The uncertainty is affecting decisions across the industry. Companies including Bayer, AstraZeneca, Roche and Novartis have raised concerns about European pricing conditions and the wider investment climate, while some US-based groups have delayed or withdrawn products from Europe. The report also said France’s health authority HAS had seen a sharp decline in early-access drug applications, an indication that the commercial hesitation is beginning to affect market behaviour rather than remaining a theoretical risk.
For Europe, the problem is not simply one of industrial policy. Delayed launches can mean slower access for patients, especially where national pricing and reimbursement procedures are already lengthy. EFPIA has repeatedly argued that access to innovative medicines in Europe remains uneven and delayed, and that the region risks falling further behind unless launch conditions improve. The industry group says delayed access remains a structural problem across European healthcare systems.
The broader commercial logic is straightforward. The United States remains the most lucrative market for many innovative medicines. If US prices are tied more directly to prices secured in Europe or other lower-priced markets, companies have an incentive to sequence launches differently, prioritising the US and postponing launches elsewhere until pricing exposure becomes clearer. Executives and analysts described the evolving US policy environment as making revenue planning more difficult and increasing caution around launch timing.
That places Brussels in an awkward position. The EU has spent years arguing that it needs both faster access to medicines and a stronger life sciences base. Yet lower national pricing, slower reimbursement decisions and fragmented market access across member states have long made Europe a less attractive first-launch market than the US. The current US policy shift appears to be magnifying those existing weaknesses rather than creating them from scratch. The Commission’s own pharmaceutical reform states that one objective is to create a framework that supports competitiveness and ensures medicines reach patients while addressing market failures.
The policy implication is clear enough. If Washington’s pricing system makes lower-priced foreign launches more commercially sensitive, Europe may face even greater difficulty attracting early launches unless it becomes faster, more predictable and more coherent as a market. That does not mean Europe should simply pay more. But it does mean that access, reimbursement and industrial strategy are becoming harder to separate.
For now, the immediate story is that a US pricing change is having consequences well beyond the United States. The result is already visible in Europe’s launch pipeline. For patients, health systems and policymakers, that makes this not only a transatlantic pricing story but also a European access story.
